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Conventional therapies seem to have reached the limit of their ability to treat patients 
with Systemic Lupus Erythematosus (SLE). To improve the outcome for these patients, new 
drugs are needed. Several attempts have been made to introduce targeted therapies for this 
complex disease. One of these targets is Interferon (IFN) alpha, whose production is increased 
in SLE, contributing to its pathogenesis. In this review we consider some recent advances in 
IFN alpha targeting-approaches. 
Three monoclonal antibodies (mAbs) against several IFN alpha subtypes have been 
tested in phase I and II trials, showing an acceptable safety profile and promising results in 
terms of reducing the IFN signature and disease activity. A mAb specific for the IFN alpha 
receptor and active immunization against IFN alpha are also being tested. Further trials will be 
essential to ascertain the safety and efficacy of all these approaches. 
1. Introduction 
Systemic Lupus Erythematosus (SLE) is a challenging autoimmune rheumatic disease. 
Its aetiology is multifactorial with evidence of genetic susceptibility, environmental triggers and 
disturbances in both innate and adaptive immunity [1]. The outcome for patients with SLE has 
improved considerably in the past 60 years. However, the 15-year survival is approximately 
85% and, as most SLE patients develop the disease under 45 years of age, the mortality and 
morbidity figures remain unsatisfactory [2]. 
We have published an analysis of our experience in managing Lupus nephritis over the 
past 30 years [3], which suggests that we have reached the optimal capacity of steroids and 
conventional immunosuppressive drugs to treat our patients. Unfortunately the major advances 
in the treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis that 
have been brought about by the introduction of targeted therapies, have not been replicated, to 
date, in patients with SLE. 
Several attempts have, however, been made to introduce therapies directed at specific 
targets in Lupus patients. The first of these, rituximab, which blocks the CD20 molecule, is 
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widely regarded as being useful in treating SLE but failed to meet its endpoints in two major 
clinical trials [4,5]. It appears that another major trial involving a B-cell blocking drug, 
epratuzumab (which binds the CD22 molecule) has not met its endpoints though full results 
have not yet been published.  Belimumab, which blocks BAFF, a B-cell activator factor, has 
been shown to be effective in SLE patients, particularly in those with joint and skin disease [6] 
and is approved by the Federal Drug Administration in the United States of America and by the 
European Medicines Agency. However it does not act rapidly and we do not yet have evidence 
of its effectiveness in treating the other aspects of SLE, such as nephritis (results from an 
ongoing trial are awaited) and neuropsychiatric involvement. Atacicept, which blocks two B-
cell activating factors, BAFF and APRIL, has shown some benefit in preventing lupus flares [7] 
but whether it is effective in treating active disease is not yet known. In addition to these 
approaches, attempts have been made to block Interferon (IFN) alpha in patients with Lupus. 
1.1 IFN alpha 
Interferons (IFNs) are glycoproteins produced by nucleated cells in response to 
pathogens, such as viruses. They are named in reference to their ability to interfere with viral 
infection [8]. 
There are three families of interferons, namely type I interferon family (IFN I), which 
includes IFN alpha, beta, epsilon, kappa and omega; type II interferon termed IFN gamma; and 
the most recently discovered type III interferons, comprising IFN delta 1 (or Interleukin (IL)-
29), IFN delta 2 (or IL-28A) and IFN delta 3 (or IL-28B) [9]. 
IFN alpha is a group of homologous proteins encoded by 13 different genes on 
chromosome 9p. All IFN I molecules bind to a single receptor, the IFN alpha receptor (IFNAR), 
which has two subunits (IFNAR1 and IFNAR2), and is expressed in virtually all tissues. 
Although most nucleated cells can produce IFN I when appropriately stimulated, plasmacytoid 
dendritic cells (pDCs) are the most abundant producers of IFN alpha, on a per cell basis [9-11]. 
IFN I is constitutively expressed at low levels. Following a viral infection, viral nucleic 
acids bind two intracellular systems: the Toll-like receptor (TLR) interferon-inducing system 
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(namely TLR7/8 and TLR9, which recognize RNA and DNA, respectively) present in the 
endosomes of monocytes, macrophages and DCs; and a cytosolic system which comprises 
several pathogen-recognition receptors that are ubiquitously expressed. This triggers a cascade 
of events that results in phosphorylation of an interferon regulatory factor which then 
translocates to the nucleus and causes rapid and potent transcription of IFN alpha. After its 
extracellular release, IFN alpha binds to the membrane-bound IFNAR, causing the activation of 
several signalling pathways, particularly the Janus kinases (JAK) and signal transducers and 
activators of transcription (STAT) pathways [8-10]. This activation results in the expression of 
IFN regulated genes, inducing an antiviral state in cells by suppressing mechanisms for viral 
replication; triggering apoptosis in virally infected cells; promoting natural killer cell-mediated 
and CD8+ T-cell mediated cytotoxicity; promoting the transition from innate to acquired 
immunity by augmenting dendritic cell (DC) maturation, cross-presentation of antigens and 
migration; enhancing T-helper type 1 responses, generation of T follicular helper cells, and the 
humoral responses [9]. 
Research has shown IFN I is not just a group of antiviral peptides (used in the treatment 
of chronic viral infections by hepatitis B and C virus), but actually a group of pleiotropic 
cytokines, with antitumor and immunoregulatory functions. IFN I has also been used in the 
treatment of malignancies and multiple sclerosis [9]. 
However, besides these beneficial effects in some infections, malignancies and 
autoimmune/inflammatory diseases, there is evidence that, paradoxically, depending on the 
context, IFN I can be detrimental for the host by promoting autoimmunity and inflammation [9]. 
In fact, several studies suggest a role for IFN I in the pathogenesis of SLE, Myositis and 
Systemic Sclerosis [12-14]. 
1.2 IFN alpha and SLE  
The association of IFN alpha with SLE was discovered around three decades ago, when 
increased levels of this protein were found in sera of SLE patients [11]. Animal models of 
Lupus have also supported this association [15]. 
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A possible causative relation between IFN alpha and SLE was suggested by the 
observation that IFN alpha pharmacotherapy for chronic viral infections or malignancies could 
lead to the development of antinuclear antibodies (inducing anti-dsDNA antibodies) and SLE 
[8,11,16]. Subsequently, transcriptome analyses have reported the up-regulation of multiple IFN 
alpha dependent genes in peripheral blood mononuclear cells from SLE patients, which is 
known as the IFN signature. As there is an overlap in the genes that type I and type II IFNs 
control, it can be difficult to distinguish between the signatures of IFN alpha, beta or gamma 
[8]. This IFN signature has been identified in almost all paediatric SLE patients and in about 50 
to 80 % of adult patients [8]. It provides a pharmacodynamic marker to assess the activity of 
anti-IFN alpha therapy in vivo [8]. 
Although the expression levels of IFN-regulated genes have correlated with SLE 
severity in cross-sectional studies, longitudinal studies have not linked disease activity with 
individual patient levels [8,11]. 
The cause for the increased IFN alpha production in SLE remains uncertain [8]. 
Increased apoptosis and tissue damage combined with decreased clearance of apoptotic bodies 
may cause an increased load of immunogenic particles containing endogenous nucleic acids. 
Circulating anti-nucleic acids autoantibodies (such as anti-dsDNA) form immune complexes 
with these particles, which are then endocytosed by pDCs through the Fc gamma receptor IIa 
(FcγRIIa), activate TLR7 and TLR9, and cause the triggering of IFN alpha production [8,9,11]. 
Neutrophils and antimicrobial autoantibodies trapped in immune complexes can also induce the 
production of IFN alpha by pDCs [8,11]. Recently, neutrophils have gained attention as another 
important source of IFN alpha [8,17]. Finally, there may be a genetic contribution to the 
increased or sustained secretion of IFN alpha. In fact, several genetic polymorphisms implicated 
in the IFN I pathway have been associated with SLE [8,11]. 
There are multiple mechanisms associated with the pathogenic role of IFN alpha in the 
context of SLE.  IFN alpha may facilitate humoral autoimmunity by generating T-follicular 
helper cells that are effective in activating B cells and antibody production. It may also enhance 
BAFF expression, B cell differentiation, Ig class-switching, and the survival of autoimmune B 
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cells. Other possible mechanisms include the inhibition of the T regulatory cell 
immunosuppressive activity; activation of immature DCs, breaking peripheral tolerance to self-
antigens; promotion of T-helper type 1 (Th1) differentiation; promotion of cytotoxicity 
mediated by natural killer and CD8+ cells; inducing production of chemokines that facilitate 
migration of inflammatory cells into target tissues; and priming myeloid cells for enhanced 
responses to inflammatory stimuli [9,11]. IFN alpha also affects the vasculature and is 
associated with atherosclerosis in SLE patients [8,11]. 
2. IFN alpha targeting approaches 
Given the pathogenic role of IFN alpha in SLE, agents that target its pathway are 
currently in development for the treatment of this disease. 
2.1 Anti-IFN alpha antibodies 
Sifalimumab 
Sifalimumab (MEDI-545), developed by AstraZeneca/MedImmune, is a fully human 
monoclonal antibody (mAb) that binds to multiple IFN alpha sub-types and inhibits their actions 
[10,18]. It has been tested in both phase I and II trials. 
A phase Ia multicentre, randomised study was conducted in adults with mildly to 
moderately active SLE, with a mean Safety of Estrogens in Lupus Erythematosus: National 
Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score 
around 5 [19,20]. Subjects received one intravenous (IV) dose of sifalimumab (n=33 blinded 
phase, 0.3, 1, 3, 10 or 30 mg/kg; n=17 open-label, 1, 3, 10 or 30 mg/kg) or placebo (n=17).  
Adverse events (AEs) were similar between groups and no increase in infections or reactivation 
was observed [19]. The investigators observed specific and dose-dependent inhibition of the 
IFN signature and related proteins in the whole blood and skin lesions from SLE patients 
[19,20]. 
The safety and tolerability of multiple intravenous doses of sifalimumab were then 
confirmed in a phase Ib trial, in patients with moderate-to-severe SLE (SELENA-SLEDAI ≥6 or 
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a British Isles Lupus Assessment Group (BILAG) score of at least one A or two Bs). Subjects 
were randomized to receive IV sifalimumab (n=121: 0.3, 1.0, 3.0, or 10.0 mg/kg) or placebo 
(n=40) every 2 weeks to week 26, then followed up for more 24 weeks [21]. There was no 
difference in the frequency of serious adverse events (SAEs) between placebo and sifalimumab 
groups. Viral infections were more frequent in the combined sifalimumab group. Five deaths 
occurred, one in the placebo group and four in the sifalimumab 10 mg/Kg group. Inhibition of 
IFN signature by sifalimumab was incomplete in these patients with moderate-to-severe active 
SLE, which may reflect the contribution of other subtypes of type I IFN (sifalimumab does not 
inhibit beta and delta IFNs, as well as some subtypes of IFN alpha) [21]. Alternatively, it may 
also suggest that this signature is driven by type II or III IFNs [8,22,23]. Immunogenicity was 
also evaluated and, although 24% of patients receiving sifalimumab had antisifalimumab 
antibodies, there was no impact on sifalimumab pharmacokinetics [21]. 
A study on the population pharmacokinetics of sifalimumab evaluated fixed versus 
body weight – based regimens and demonstrated the viability of switching to fixed doses in 
phase IIb clinical trials [24]. 
Subsequently, a phase IIb randomized, double-blind, placebo-controlled study in adults 
with seropositive moderate-to-severe SLE (minimum disease activity for entry: SLEDAI-2K ≥6 
and 1 BILAG A or 2 Bs and physician’s global assessment ≥1) was carried out and the results 
were presented at the 2014 American College of Rheumatology (ACR) annual meeting [25]. 
Subjects (n=431) were randomized (1:1:1:1) to receive monthly IV sifalimumab 200, 600, 1200 
mg or placebo, for one year. Randomization was stratified by disease activity, IFN signature, 
and geographic region. The primary efficacy endpoint, which was the presence of an SLE 
Responder Index (SRI) – 4 at day 365, was achieved. 
The SRI is a composite index which was developed for the trials of belimumab in SLE 
[26]. It is defined as a ≥ 4-point reduction in SELENA-SLEDAI score, with no new BILAG A 
or no more than 1 new BILAG B domain score, and no deterioration from baseline in the 
physician's global assessment by ≥ 0.3 points. In this sifalimumab trial, the percentage of 
patients with a SRI – 4 response was 58.3%, 56.5% and 59.8% for sifalimumab 200, 600 and 
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1200 mg, respectively, versus 45.4% for placebo (effect size 1200mg versus placebo 14.4%, 
p=0.031). Analyses of more stringent SRI (6–8) endpoints demonstrated even greater 
discrimination between the 1200 mg dose and placebo. There were also significant 
improvements in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), 
joint counts and Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue scores. 
Baseline low complement levels and elevated anti-dsDNA levels did not normalize over time. 
According to the abstract presented, reported AEs were similar across groups, except for Herpes 
zoster which occurred more frequently in sifalimumab groups (200 mg, 4.6%; 600 mg, 3.7%; 
1200 mg, 8.4%) versus placebo (0.9%) [25]; the full report of this study is awaited. 
Geographic differences were assessed, in this worldwide phase IIb study, as potential 
confounders of efficacy [27]. Data was grouped into two regions: Region 1: high expected 
response to standard of care (SOC) Central America, South America, Eastern Europe, Asia; 
Region 2: low expected SOC response North America, Western Europe, South Africa. Greater 
response rates were observed in Region 1 than in Region 2. The authors suggest these results 
may be reflective of different baseline characteristics between populations or differences in 
SOC [27]. 
Subcutaneous (SC) administration of sifalimumab was also tested in phase II studies 
[28,29]. The safety profile of multiple SC doses of sifalimumab was assessed in a multicenter, 
randomized, double-blind, placebo-controlled study with 87 SLE patients [28]. It showed no 
major differences comparing to placebo. Also, an inhibition of IFN I signature by SC 
sifalimumab was observed in whole blood. The pharmacokinetic and pharmacodynamic effect 
of SC sifalimumab was also assessed in two open label trials with Japanese patients and showed 
the expected mechanism of action in SLE [29]. 
Rontalizumab 
Rontalizumab (RG-7415), developed by Roche/Genentech, is a humanized mAb that 




The safety and pharmacodynamics of rontalizumab was assessed in a phase I placebo-
controlled, double-blind, dose-escalation study [30]. Patients with mildly active (mean 
SELENA-SLEDAI=3.4) seropositive SLE (n=60; ratio of 4:1 for active treatment to placebo) 
were enrolled into dose groups ranging from 0.3 to 10 mg/kg, administered via IV or SC routes. 
Rontalizumab was generally well tolerated and none of the AEs that occurred led to 
discontinuation of the study drug. Exposure-adjusted rate of infections was similar between 
groups. Although the proportion of reported SAEs was higher in the rontalizumab group (8.3 
versus 14.6%), none of these SAEs were considered to be related to the study drug. One case of 
malignancy (acute myelogenous leukemia) was reported in a patient in the 3 mg/kg SC cohort. 
A decline in IFN signature was observed following treatment with the higher IV doses, 
however, none of the patients reached the levels seen in healthy individuals. Furthermore, 
autoantibody levels did not decline following administration of rontalizumab. It is likely that 
these autoantibodies are derived, at least in part, from long-lived plasma cells, and longer 
treatment periods may be required [30]. 
In a phase II study, the efficacy and safety of rontalizumab was studied in patients with 
moderate-to-severe active SLE (at least 1 BILAG A or 2 Bs) [31]. Exclusion criteria included 
active lupus nephritis and unstable neuropsychiatric lupus. Patients (n=238) were randomised 
(2:1) into two sequential cohorts to receive 750 mg IV rontalizumab every 4 weeks (n=81) or 
placebo (n=41) (Part 1), and 300 mg subcutaneous rontalizumab every 2 weeks (n=78) or 
placebo (n=38) (Part 2). Immunosuppressants were discontinued at randomisation and steroids 
were tapered to ≤10 mg/day by week 6 after randomisation. Both Part 1 and 2 lasted 24 weeks 
and were followed by an open-label safety extension study – Part 3 (up to 144 weeks). Neither 
the primary and secondary efficacy end points (reduction in BILAG-2004 and SRI, respectively, 
at Week 24) were met. However, in an exploratory analysis, rontalizumab treatment was 
associated with improvements in disease activity (SRI response), reduced flares (SELENA-
SLEDAI) and decreased steroid use within a subpopulation who had a low IFN signature at the 
baseline. The authors suggest the lack of response in patients with high IFN signature could be 
due to inadequacy of dose or complex multipathway disease in that subpopulation [31]. The 
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incidence of reported AEs, SAEs and infectious AEs were comparable between the placebo and 
rontalizumab groups. Nausea was more common in the rontalizumab group (8% versus 4%). 
Four placebo and six rontalizumab patients discontinued study drug due to an AE (5.1% and 
3.8% respectively). There were two deaths during the open label extension but they were 
attributed to complications of SLE. One malignancy was reported in the placebo IV group. The 
rate of SLE flares that were SAEs (defined according to the revised SELENA-SLEDAI Flare 
Index (SFI-R) instrument) was higher in the rontalizumab (6%) compared with placebo (1%) 
groups. All of these flare SAEs occurred in patients with high IFN signature. Antibodies against 
rontalizumab were identified in 3% of patients, but had no apparent impact on pharmacokinetics 
or safety [31]. 
 
AGS-009 
AGS-009 (Argos Therapeutics) is a humanized mAb which neutralizes several IFN 
alpha subtypes. Its safety was evaluated in a multicenter, randomized, double blind, placebo-
controlled, phase Ia single dose escalation study [32] and the results were presented at the 2012 
European League Against Rheumatism (EULAR) Congress as a poster. Twenty five patients 
with mild-to-moderate (mean SLEDAI=4.1) seropositive SLE were randomized in 3:1 ratio 
within each cohort to receive a single IV dose of AGS-009 (0.01, 0.1, 0.6, 3, 10 or 30 mg/kg) or 
placebo in combination with standard of care. This mAb showed to be safe and well tolerated at 
each dose level. It resulted in significant neutralization of IFN signature at doses above 0.6 
mg/Kg [32]. 
Despite these promising results, no more data have yet been published about AGS-009. 
2.2 Anti-IFN alpha receptor antibodies 
Anifrolumab 
Anifrolumab (MEDI-546), developed by AstraZeneca/MedImmune, is a mAb specific 
for IFNAR1. The results of a phase II, open label, dose escalation study in 17 Japanese SLE 
patients were presented at the 2014 ACR annual meeting [29]. Patients were randomized to 
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receive 100, 300 or 1000 mg of IV anifrolumab, administered every four weeks. Blood samples 
for assessment of pharmacokinetics and pharmacodynamics were collected at multiple time 
points until day 169. Anifrolumab showed nonlinear pharmacokinetics. Its administration 
resulted in an increased and more sustained suppression of IFN signature, compared to 
sifalimumab. There were no major safety issues, however, this small open label study does not 
allow an adequate characterization of anifrolumab’s safety profile [29]. Larger studies are 
ongoing. 
2.3 IFN alpha Kinoid 
The IFN alpha Kinoid (IFN-K), developed by Neovacs, is a therapeutic vaccine 
composed of inactivated IFN alpha coupled to a carrier protein, the keyhole limpet hemocyanin. 
It induces the formation of anti-IFN alpha polyclonal antibodies which neutralize most or all 
IFN alpha subtypes but neither IFN beta nor gamma [33]. 
A multicenter, randomized, double-blind, placebo-controlled, phase I/II dose-escalation 
study [34] assessed the safety, immunogenicity and biologic effects of IFN-K in 28 seropositive 
SLE patients with mild-to-moderate active disease (SLEDAI-2K scores between 4 and 10). The 
patients were randomized to receive three or four doses of IFN-K 30 μg (n=3), 60 μg (n=6), 120 
μg (n=6), 240 μg (n=6), or placebo (n=7). IFN-K was well tolerated. There were two reported 
SAEs, both corresponding to SLE flares. One of them occurred in a subject who received 
placebo and the other one in a patient who received one dose of IFN-K 240 μg. However, the 
investigators consider that the later is likely linked to abrupt stopping of corticosteroids. No 
severe infections were reported. IFN-K showed to induce anti-IFN alpha antibodies and to 
down-regulate IFN related genes in SLE patients with a high IFN signature at baseline. The 
anti-IFN alpha antibody production in patients treated with IFN-K was associated with an 
increase in complement C3 levels. There was, however, no significant observed effect in anti-
dsDNA levels or in disease activity evaluated by SLEDAI or BILAG during the six-month 




The generation of the IFN signature is a complex process. The phase Ib trial with 
sifalimumab suggested that IFN signature is more refractory to inhibition in patients with more 
active disease. Unexpectedly, rontalizumab was not effective in improving clinical disease 
activity in patients with a high IFN signature, who had higher levels of anti-dsDNA antibodies, 
increased consumption of complement and higher expression of antibodies against extractable 
nuclear antigens. These findings suggest that, in SLE patients with more active disease, several 
mechanisms may contribute to the expression of IFN related genes. Thus, drugs with broader 
targets may have a higher probability of effectiveness. 
Sifalimumab, rontalizumab and AGS-9 neutralize numerous IFN alpha subtypes; 
however, studies suggest that some IFN alpha activity persists, which could be due to 
insufficient neutralization of some IFN alpha subtypes. IFN-K induces the formation of 
polyclonal antibodies which neutralize most or all IFN alpha subtypes, but not other types of 
IFN. Furthermore, it was shown to induce higher production of antibodies in the patients who 
have stronger IFN signature at baseline, suggesting that IFN-K can neutralize IFN alpha activity 
even in these patients. Anifrolumab, which inhibits the IFNAR, will, in theory, neutralize all 
IFN I activity, including IFN beta. Whether this will be an advantage leading to better clinical 
response, or a liability, leading to increased risk of adverse events, namely severe viral 
infections, is yet to be known. 
4. Conclusion 
Current evidence shows that IFN alpha is involved in the pathogenesis of SLE; 
therefore, it would seem logical to use drugs that block IFN alpha to treat SLE. Given that many 
B-cell targeting therapies have failed to meet the endpoints in the clinical trials, IFN targeting 
therapies may constitute valuable alternatives. As they act upstream in the pathways that lead, 
not only to activation of B-cells, but also to other mechanisms involved in this complex disease, 
it is reasonable to postulate that IFN targeting therapies will be more effective in controlling the 
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diverse features of SLE than B-cell targeting drugs. However, more information is required 
about any additional burden of adverse events. So far, they have shown acceptable short-term 
safety in phase I and II studies, but phase III trials will be essential to ascertain better their 
safety profile and clinical efficacy. Frustratingly, although an IFN alpha blocker, Sifalimumab, 
has reported encouraging results, another one, Rontalizumab, failed to meet its primary 
endpoints. The future of IFN alpha as a target for biologic drugs in the treatment of SLE thus 
remains under careful scrutiny. 
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